Abstracts

No Evidence of Sexual Transmission of Minority HIV Drug Resistance Mutations in MSM

During primary HIV infection, the detection of minority drug resistant mutations (DRM), defined as <20% of sampled population, may be a consequence of (i) sexual transmission, (ii) de novo mutations, and/or (iii) technical errors. Baseline blood samples were collected from 32 HIV+ antiretroviral-naive, phylogenetically- and epidemiologically-linked male source and recipient partners, within a mean of…

Integrase Inhibitors-Transmitted Drug Resistance Detected by UltraDeep Sequencing

Transmitted Drug Resistance (TDR) can impair first-line antiretroviral therapy response. Moreover, HIV-1 minority resistant variants (MRV) can be a source of virological failure if they are present before antiretroviral treatment: it was mainly shown for non nucleoside reverse transcriptase inhibitors first line based regimens. Few data are available for TDR Integrase Strand Transfer Inhibitors (ISTIs).…

Linkage of Rare Drug Resistance Mutations Detected by New Ultrasensitive SGS

Targeted next generation sequencing (NGS) is a powerful tool for detecting low frequency, HIV-1 drug-resistant mutations but frequent in vitro recombination prevents accurate detection of linked mutations and assessment of phylogenetic relationships. We developed a new NGS-based ultrasensitive single-genome sequencing (uSGS) assay that eliminates in vitro recombinants and reduces PCR errors to investigate linkage of…

New ARVs Could Represent More Than USD 3 Billion in Cost Savings Through 2025

Several new antiretrovirals (ARVs) are likely to be introduced in low-and middle-income countries (LMICs) by 2019 that represent a range of clinical and cost advantages to current products. These include tenofovir alafenamide fumarate (TAF), low dose efavirenz (EFV400), and dolutegravir (DTG). As programs evaluate adoption of these products, it is important that they understand the…